28
March 2019, London, U.K.
GSK
publishes product sales reporting changes and the impact
of IFRS 16 'Leases'
|
GSK
keeps its financial reporting under regular review to ensure that
it remains current and in line with both the latest regulatory
requirements and developing best practice within the Pharmaceutical
industry.
Respiratory category for reported sales to be updated
Following
the approval of a generic alternative to Advair in the US, GSK has reviewed
the presentation of its respiratory product sales and will report
the Ellipta products portfolio
and Nucala under
the "Respiratory" category and all other respiratory products under
"Established Pharmaceuticals" (disclosed separately as an
Established Respiratory section) with effect from the first quarter
2019 Results Announcement. This reflects the different stages
of the product life-cycle of the various respiratory products and
ensures consistency of reporting for the sales of products with
similar levels of strategic focus.
The
revised Pharmaceutical turnover tables below set out the revised
format for reporting Pharmaceutical product sales that will be used
from the first quarter 2019 results, as applied to the 2018
reported Pharmaceutical product sales.
New accounting requirements - IFRS 16 "Leases"
IFRS 16
"Leases" was issued in January 2016 and has been implemented by the
Group from 1 January 2019. The Standard replaces IAS 17 "Leases"
and will require lease liabilities and 'right of use' assets to be
recognised on the balance sheet for almost all leases. This has
resulted in a significant increase in both assets and liabilities
recognised. The costs of operating leases previously included
within operating costs will be split and the financing element of
the charge will be reported within finance expense.
GSK has
implemented IFRS 16 by applying the modified retrospective
approach. For larger leases, the right of use asset at 1 January
2019 has been calculated based on the original lease inception date
and for smaller leases the right of use asset has been set equal to
the lease liability, adjusted for any prepaid or accrued lease
payments, onerous lease provisions and business combination fair
value adjustments.
The table overleaf shows the amount of adjustment for each
financial statement line item affected by the application of IFRS
16 at 1 January 2019.
|
|
As previously reported
|
IFRS 16 adjustments
|
As adjusted
|
|
£m
|
£m
|
£m
|
Property, plant and equipment
|
11,058
|
(98)
|
10,960
|
Right of use assets
|
-
|
1,071
|
1,071
|
Other non-current assets
|
1,576
|
(11)
|
1,565
|
Trade and other receivables
|
6,423
|
3
|
6,426
|
Deferred tax assets
|
3,887
|
39
|
3,926
|
|
|
|
|
Short-term borrowings
|
(5,793)
|
(229)
|
(6,022)
|
Long-term borrowings
|
(20,271)
|
(1,074)
|
(21,345)
|
|
|
|
|
Trade and other payables
|
(14,037)
|
10
|
(14,027)
|
Current and non-current provisions
|
(1,423)
|
35
|
(1,388)
|
Other non-current liabilities
|
(938)
|
160
|
(778)
|
Deferred tax liabilities
|
(1,156)
|
1
|
(1,155)
|
|
|
|
|
Total effect on net assets
|
3,672
|
(93)
|
3,579
|
|
|
|
|
|
|
|
|
Retained earnings
|
(2,137)
|
(93)
|
(2,230)
|
|
|
|
|
Total effect on equity
|
3,672
|
(93)
|
3,579
|
The
IFRS 16 impact tables below set out, on a pro forma basis, the
impact of IFRS 16 on the Total and Adjusted results for the
quarters of 2018 assuming the same transition adjustments were made
as at 1 January 2018 instead of 1 January 2019. The impact of the
change would have been to increase the operating profit on a Total
basis by £18 million and on an Adjusted basis by £23
million in 2018 and to increase the net finance expense by £28
million on a Total basis and £30 million on an Adjusted
basis.
The impact of IFRS 16 for the full years 2019 and 2020 is expected
to be at a similar level to 2018, and so this change is not
expected to affect the Group's previously announced guidance
related to its expectations for Adjusted EPS growth in CER
terms for 2019 or the Group's medium-term outlook for Adjusted
EPS growth in CER terms for the five year period
2016-2020.
An Excel version of this data is available
on www.gsk.com.
|
|
GSK - one
of the world's leading research-based pharmaceutical and healthcare
companies - is committed to improving the quality of human life by
enabling people to do more, feel better and live longer. For
further information please visit www.gsk.com
|
|
|
|
|
Analyst/Investor
enquiries:
|
Sarah
Elton-Farr
|
+44 (0)
20 8047 5194
|
(London)
|
|
James
Dodwell
|
+44 (0)
20 8047 2406
|
(London)
|
|
Danielle
Smith
|
+44 (0)
20 8047 7562
|
(London)
|
|
Jeff
McLaughlin
|
+1 215
751 7002
|
(Philadelphia)
|
This Announcement does not constitute statutory accounts of the
Group within the meaning of sections 434(3) and 435(3) of the
Companies Act 2006. The information for 2018 has been derived
from the full Group accounts published in the Annual Report
2018.
CER growth
In order to illustrate underlying performance, it is the Group's
practice to discuss its results in terms of constant exchange rate
(CER) growth. This represents growth calculated as if the exchange
rates used to determine the results of overseas companies in
Sterling had remained unchanged from those used in the comparative
period.
|
Assumptions related to 2019 guidance and 2016-2020
outlook
In
outlining the expectations for 2019 and the five-year period
2016-2020, the Group has made certain assumptions about the
healthcare sector, the different markets in which the Group
operates and the delivery of revenues and financial benefits from
its current portfolio, pipeline and restructuring
programmes.
For the
Group specifically, over the period to 2020, GSK expects further
declines in sales of Seretide/Advair. The introduction of a generic
alternative to Advair in the US has been factored into the Group's
assessment of its future performance. The Group assumes no
premature loss of exclusivity for other key products over the
period.
The
assumptions for the Group's revenue, earnings and dividend
expectations assume no material interruptions to supply of the
Group's products, no material mergers, acquisitions or disposals,
except for the acquisition of Tesaro, the proposed divestment of
Horlicks and other Consumer Healthcare products to Unilever and the
proposed formation of a new Consumer Healthcare Joint Venture with
Pfizer, all announced in December 2018, no material litigation or
investigation costs for the Company (save for those that are
already recognised or for which provisions have been made), no
share repurchases by the Company, and no change in the Group's
shareholdings in ViiV Healthcare. The assumptions also assume no
material changes in the macro-economic and healthcare environment.
The 2019 guidance and 2016-2020 outlook have factored in all
divestments and product exits since 2015, including the divestment
and exit of more than 130 non-core tail brands (£0.5 billion
in annual sales) as announced on 26 July 2017 and the product
divestments planned in connection with the proposed Consumer
Healthcare transaction with Pfizer.
The
Group's expectations assume successful delivery of the Group's
integration and restructuring plans over the period 2016-2020,
including the extension and enhancement to the combined programme
announced on 26 July 2017 as well as the new major restructuring
plan announced on 25 July 2018.
They
also assume that the proposed Consumer Healthcare nutrition
disposal closes by the end of 2019 and the proposed Consumer
Healthcare Joint Venture with Pfizer closes during H2 2019 and that
the integration and investment programmes following the Tesaro
acquisition and the proposed Consumer Healthcare Joint Venture with
Pfizer over this period are delivered successfully.
Material
costs for investment in new product launches and R&D have been
factored into the expectations given. Given the potential
development options in the Group's pipeline, the outlook may be
affected by additional data-driven R&D investment decisions.
The expectations are given on a constant currency basis (2016-2020
outlook at 2015 CER).
Subject
to material changes in the product mix, the Group's medium-term
effective tax rate is expected to be around 19% of Adjusted
profits. This incorporates management's best estimates of the
impact of US tax reform on the Group based on the information
currently available. As more information on the detailed
application of the US Tax Cuts and Jobs Act becomes available, the
assumptions underlying these estimates could change with consequent
adjustments to the charges taken that could have a material impact
on the results of the Group.
Cautionary statement regarding forward-looking
statements
The
Group's reports filed with or furnished to the US Securities and
Exchange Commission (SEC), including this document and written
information released, or oral statements made, to the public in the
future by or on behalf of the Group, may contain forward-looking
statements. Forward-looking statements give the Group's current
expectations or forecasts of future events. An investor can
identify these statements by the fact that they do not relate
strictly to historical or current facts. They use words such as
'anticipate', 'estimate', 'expect', 'intend', 'will', 'project',
'plan', 'believe' and other words and terms of similar meaning in
connection with any discussion of future operating or financial
performance. In particular, these include statements relating to
future actions, prospective products or product approvals, future
performance or results of current and anticipated products, sales
efforts, expenses, the outcome of contingencies such as legal
proceedings, and financial results. Other than in accordance with
its legal or regulatory obligations (including under the UK Listing
Rules and the Disclosure and Transparency Rules of the Financial
Conduct Authority), the Group undertakes no obligation to update
any forward-looking statements, whether as a result of new
information, future events or otherwise. The reader should,
however, consult any additional disclosures that the Group may make
in any documents that it publishes and/or files with the SEC. All
readers, wherever located, should take note of these disclosures.
Accordingly, no assurance can be given that any particular
expectation will be met and shareholders and investors are
cautioned not to place undue reliance on the forward-looking
statements.
Forward-looking
statements are subject to assumptions, inherent risks and
uncertainties, many of which relate to factors that are beyond the
Group's control or precise estimate. The Group cautions investors
that a number of important factors, including those in this
document, could cause actual results to differ materially from
those expressed or implied in any forward-looking statement. Such
factors include, but are not limited to, those discussed under
'Principal risks and uncertainties' on pages 257-266 of the GSK
2018 Annual Report. Any forward-looking statements made by or on
behalf of the Group speak only as of the date they are made and are
based upon the knowledge of and information available to the
Directors on the date of this report.
|
|
|
|
Registered in England & Wales:
No. 3888792
|
|
|
|
Registered Office:
980 Great West Road
Brentford, Middlesex
TW8 9GS
|
|
Revised format for reporting Pharmaceuticals product
sales
The
revised format for the reporting of Pharmaceutical product sales
applied to the 2018 Pharmaceutical sales is as
follows:
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
2,612
|
35
|
38
|
1,586
|
28
|
31
|
609
|
55
|
54
|
417
|
40
|
45
|
Ellipta products
|
2,049
|
29
|
32
|
1,245
|
24
|
27
|
457
|
42
|
41
|
347
|
33
|
38
|
Anoro Ellipta
|
476
|
39
|
42
|
318
|
36
|
39
|
101
|
46
|
45
|
57
|
46
|
54
|
Arnuity Ellipta
|
44
|
26
|
29
|
39
|
22
|
25
|
-
|
-
|
-
|
5
|
67
|
67
|
Incruse Ellipta
|
284
|
41
|
44
|
186
|
39
|
42
|
74
|
45
|
45
|
24
|
50
|
56
|
Relvar/Breo Ellipta
|
1,089
|
8
|
10
|
581
|
(3)
|
(1)
|
253
|
25
|
24
|
255
|
26
|
31
|
Trelegy Ellipta
|
156
|
>100
|
>100
|
121
|
>100
|
>100
|
29
|
>100
|
>100
|
6
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
563
|
64
|
66
|
341
|
44
|
48
|
152
|
>100
|
>100
|
70
|
84
|
89
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
4,722
|
9
|
11
|
2,913
|
8
|
10
|
1,194
|
7
|
6
|
615
|
14
|
20
|
Dolutegravir products
|
4,420
|
14
|
16
|
2,830
|
11
|
13
|
1,091
|
18
|
17
|
499
|
28
|
35
|
Tivicay
|
1,639
|
17
|
19
|
1,036
|
12
|
15
|
377
|
20
|
18
|
226
|
37
|
47
|
Triumeq
|
2,648
|
8
|
9
|
1,670
|
2
|
5
|
706
|
17
|
15
|
272
|
21
|
25
|
Juluca
|
133
|
>100
|
>100
|
124
|
>100
|
>100
|
8
|
-
|
-
|
1
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
117
|
(50)
|
(48)
|
7
|
(74)
|
(74)
|
44
|
(61)
|
(61)
|
66
|
(28)
|
(24)
|
Selzentry
|
115
|
(10)
|
(9)
|
58
|
(12)
|
(11)
|
35
|
(17)
|
(17)
|
22
|
10
|
15
|
Other
|
70
|
(41)
|
(40)
|
18
|
(59)
|
(59)
|
24
|
(35)
|
(38)
|
28
|
(26)
|
(21)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
472
|
25
|
28
|
420
|
24
|
27
|
36
|
33
|
33
|
16
|
45
|
64
|
Benlysta
|
473
|
26
|
29
|
420
|
24
|
27
|
37
|
37
|
33
|
16
|
60
|
80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
9,463
|
(11)
|
(8)
|
2,534
|
(23)
|
(21)
|
2,233
|
(9)
|
(10)
|
4,696
|
(4)
|
1
|
Established
Respiratory
|
4,316
|
(15)
|
(13)
|
1,782
|
(23)
|
(21)
|
924
|
(13)
|
(14)
|
1,610
|
(4)
|
-
|
Seretide/Advair
|
2,422
|
(23)
|
(21)
|
1,097
|
(32)
|
(30)
|
599
|
(19)
|
(20)
|
726
|
(7)
|
(4)
|
Flixotide/Flovent
|
595
|
-
|
3
|
333
|
3
|
6
|
93
|
(2)
|
(3)
|
169
|
(5)
|
1
|
Ventolin
|
737
|
(4)
|
(1)
|
352
|
(7)
|
(5)
|
130
|
(2)
|
(2)
|
255
|
-
|
7
|
Avamys/Veramyst
|
300
|
7
|
10
|
-
|
-
|
-
|
74
|
(3)
|
(4)
|
226
|
11
|
16
|
Other Respiratory
|
262
|
(9)
|
(7)
|
-
|
-
|
-
|
28
|
4
|
-
|
234
|
(9)
|
(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
435
|
(4)
|
-
|
3
|
(57)
|
(57)
|
161
|
(1)
|
(2)
|
271
|
(5)
|
2
|
Augmentin
|
570
|
(3)
|
2
|
-
|
-
|
-
|
181
|
(1)
|
(2)
|
389
|
(4)
|
3
|
Avodart
|
572
|
(7)
|
(5)
|
12
|
(20)
|
(20)
|
240
|
(19)
|
(20)
|
320
|
6
|
11
|
Imigran/Imitrex
|
141
|
(16)
|
(16)
|
58
|
(25)
|
(23)
|
57
|
(12)
|
(14)
|
26
|
-
|
-
|
Lamictal
|
617
|
(5)
|
(3)
|
310
|
(7)
|
(5)
|
113
|
6
|
5
|
194
|
(8)
|
(4)
|
Seroxat/Paxil
|
170
|
(8)
|
(5)
|
-
|
-
|
-
|
39
|
-
|
-
|
131
|
(10)
|
(7)
|
Valtrex
|
123
|
(4)
|
(1)
|
21
|
5
|
5
|
30
|
3
|
3
|
72
|
(9)
|
(4)
|
Other
|
2,519
|
(6)
|
(9)
|
348
|
(34)
|
(32)
|
488
|
(3)
|
(4)
|
1,683
|
(4)
|
1
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
17,269
|
-
|
2
|
7,453
|
(2)
|
1
|
4,072
|
2
|
1
|
5,744
|
-
|
5
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals turnover - three months ended 31 December
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
827
|
38
|
34
|
520
|
32
|
27
|
179
|
58
|
57
|
128
|
36
|
35
|
Ellipta products
|
654
|
36
|
33
|
413
|
33
|
28
|
135
|
52
|
51
|
106
|
33
|
31
|
Anoro Ellipta
|
144
|
32
|
28
|
98
|
27
|
21
|
29
|
45
|
45
|
17
|
42
|
50
|
Arnuity Ellipta
|
13
|
8
|
-
|
11
|
10
|
10
|
-
|
-
|
-
|
2
|
-
|
(50)
|
Incruse Ellipta
|
87
|
43
|
38
|
60
|
46
|
39
|
20
|
33
|
33
|
7
|
40
|
40
|
Relvar/Breo Ellipta
|
333
|
13
|
9
|
186
|
3
|
(2)
|
71
|
31
|
28
|
76
|
25
|
26
|
Trelegy Ellipta
|
77
|
>100
|
>100
|
58
|
>100
|
>100
|
15
|
>100
|
>100
|
4
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
173
|
43
|
38
|
107
|
29
|
23
|
44
|
83
|
79
|
22
|
57
|
57
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,276
|
10
|
6
|
786
|
10
|
3
|
317
|
9
|
7
|
173
|
15
|
18
|
Dolutegravir products
|
1,205
|
14
|
9
|
766
|
11
|
5
|
291
|
15
|
13
|
148
|
28
|
29
|
Tivicay
|
452
|
14
|
10
|
281
|
10
|
3
|
104
|
20
|
18
|
67
|
24
|
28
|
Triumeq
|
691
|
5
|
1
|
429
|
-
|
(6)
|
182
|
10
|
8
|
80
|
29
|
29
|
Juluca
|
62
|
>100
|
>100
|
56
|
>100
|
>100
|
5
|
-
|
-
|
1
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
30
|
(29)
|
(31)
|
4
|
-
|
(25)
|
11
|
(35)
|
(35)
|
15
|
(29)
|
(29)
|
Selzentry
|
31
|
3
|
(3)
|
16
|
-
|
(13)
|
9
|
(10)
|
(10)
|
6
|
50
|
50
|
Other
|
10
|
(63)
|
(52)
|
-
|
-
|
-
|
6
|
(50)
|
(50)
|
4
|
(56)
|
(33)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
136
|
40
|
34
|
121
|
39
|
31
|
10
|
43
|
43
|
5
|
67
|
>100
|
Benlysta
|
138
|
42
|
34
|
121
|
39
|
31
|
10
|
43
|
43
|
7
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,571
|
(4)
|
(5)
|
692
|
(17)
|
(22)
|
604
|
(3)
|
(4)
|
1,275
|
4
|
6
|
Established
Respiratory
|
1,164
|
(10)
|
(12)
|
503
|
(18)
|
(23)
|
236
|
(12)
|
(13)
|
425
|
3
|
4
|
Seretide/Advair
|
647
|
(18)
|
(20)
|
299
|
(27)
|
(31)
|
150
|
(18)
|
(20)
|
198
|
1
|
2
|
Flixotide/Flovent
|
166
|
2
|
-
|
94
|
3
|
(2)
|
26
|
-
|
(4)
|
46
|
2
|
7
|
Ventolin
|
215
|
-
|
(1)
|
110
|
(1)
|
(6)
|
36
|
-
|
(3)
|
69
|
1
|
7
|
Avamys/Veramyst
|
73
|
12
|
12
|
-
|
-
|
-
|
17
|
-
|
-
|
56
|
17
|
17
|
Other Respiratory
|
63
|
(5)
|
(5)
|
-
|
-
|
-
|
7
|
17
|
33
|
56
|
(2)
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
115
|
(1)
|
2
|
1
|
(80)
|
(80)
|
43
|
8
|
5
|
71
|
-
|
6
|
Augmentin
|
146
|
2
|
3
|
-
|
-
|
-
|
49
|
7
|
7
|
97
|
-
|
2
|
Avodart
|
149
|
-
|
(1)
|
3
|
-
|
(67)
|
60
|
(6)
|
(8)
|
86
|
5
|
7
|
Imigran/Imitrex
|
40
|
11
|
8
|
19
|
27
|
27
|
14
|
(7)
|
(13)
|
7
|
17
|
17
|
Lamictal
|
159
|
(5)
|
(8)
|
83
|
(2)
|
(9)
|
30
|
15
|
15
|
46
|
(19)
|
(18)
|
Seroxat/Paxil
|
46
|
(2)
|
(4)
|
-
|
-
|
-
|
10
|
-
|
-
|
36
|
(3)
|
(5)
|
Valtrex
|
33
|
6
|
6
|
7
|
75
|
50
|
7
|
17
|
17
|
19
|
(10)
|
(5)
|
Other
|
719
|
3
|
3
|
76
|
(33)
|
(34)
|
155
|
5
|
3
|
488
|
11
|
13
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,810
|
6
|
4
|
2,119
|
4
|
(1)
|
1,110
|
7
|
6
|
1,581
|
7
|
9
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceuticals turnover - nine months ended 30 September
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
1,785
|
34
|
40
|
1,066
|
26
|
33
|
430
|
54
|
53
|
289
|
42
|
50
|
Ellipta products
|
1,395
|
26
|
31
|
832
|
20
|
27
|
322
|
38
|
37
|
241
|
34
|
42
|
Anoro Ellipta
|
332
|
42
|
48
|
220
|
40
|
48
|
72
|
47
|
45
|
40
|
48
|
56
|
Arnuity Ellipta
|
31
|
35
|
43
|
28
|
27
|
32
|
-
|
-
|
-
|
3
|
>100
|
>100
|
Incruse Ellipta
|
197
|
41
|
46
|
126
|
35
|
43
|
54
|
50
|
50
|
17
|
55
|
64
|
Relvar/Breo Ellipta
|
756
|
6
|
11
|
395
|
(6)
|
(1)
|
182
|
23
|
22
|
179
|
27
|
33
|
Trelegy Ellipta
|
79
|
-
|
-
|
63
|
-
|
-
|
14
|
-
|
-
|
2
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
390
|
75
|
81
|
234
|
53
|
61
|
108
|
>100
|
>100
|
48
|
100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
3,446
|
8
|
12
|
2,127
|
7
|
13
|
877
|
7
|
6
|
442
|
14
|
21
|
Dolutegravir products
|
3,215
|
14
|
19
|
2,064
|
10
|
16
|
800
|
20
|
19
|
351
|
29
|
37
|
Tivicay
|
1,187
|
18
|
23
|
755
|
13
|
19
|
273
|
20
|
18
|
159
|
43
|
56
|
Triumeq
|
1,957
|
8
|
12
|
1,241
|
3
|
9
|
524
|
19
|
18
|
192
|
19
|
24
|
Juluca
|
71
|
-
|
-
|
68
|
-
|
-
|
3
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
87
|
(54)
|
(52)
|
3
|
(87)
|
(83)
|
33
|
(66)
|
(66)
|
51
|
(28)
|
(23)
|
Selzentry
|
84
|
(14)
|
(10)
|
42
|
(16)
|
(10)
|
26
|
(19)
|
(19)
|
16
|
-
|
6
|
Other
|
60
|
(35)
|
(37)
|
18
|
(53)
|
(53)
|
18
|
(28)
|
(32)
|
24
|
(17)
|
(17)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
336
|
20
|
26
|
299
|
19
|
25
|
26
|
30
|
30
|
11
|
37
|
50
|
Benlysta
|
335
|
21
|
27
|
299
|
19
|
25
|
27
|
35
|
30
|
9
|
29
|
71
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
6,892
|
(13)
|
(9)
|
1,842
|
(25)
|
(21)
|
1,629
|
(11)
|
(12)
|
3,421
|
(6)
|
-
|
Established
Respiratory
|
3,152
|
(16)
|
(13)
|
1,279
|
(25)
|
(21)
|
688
|
(14)
|
(15)
|
1,185
|
(6)
|
(1)
|
Seretide/Advair
|
1,775
|
(24)
|
(21)
|
798
|
(34)
|
(30)
|
449
|
(19)
|
(20)
|
528
|
(10)
|
(5)
|
Flixotide/Flovent
|
429
|
(1)
|
4
|
239
|
3
|
9
|
67
|
(3)
|
(3)
|
123
|
(8)
|
(2)
|
Ventolin
|
522
|
(5)
|
-
|
242
|
(10)
|
(5)
|
94
|
(2)
|
(2)
|
186
|
(1)
|
7
|
Avamys/Veramyst
|
227
|
5
|
9
|
-
|
-
|
-
|
57
|
(3)
|
(5)
|
170
|
9
|
15
|
Other Respiratory
|
199
|
(10)
|
(8)
|
-
|
-
|
-
|
21
|
-
|
(10)
|
178
|
(11)
|
(7)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
320
|
(6)
|
(1)
|
2
|
-
|
-
|
118
|
(3)
|
(4)
|
200
|
(7)
|
1
|
Augmentin
|
424
|
(5)
|
1
|
-
|
-
|
-
|
132
|
(3)
|
(4)
|
292
|
(5)
|
3
|
Avodart
|
423
|
(9)
|
(6)
|
9
|
(25)
|
(8)
|
180
|
(23)
|
(24)
|
234
|
7
|
12
|
Imigran/Imitrex
|
101
|
(23)
|
(23)
|
39
|
(37)
|
(35)
|
43
|
(14)
|
(14)
|
19
|
(5)
|
(5)
|
Lamictal
|
458
|
(5)
|
(1)
|
227
|
(8)
|
(3)
|
83
|
2
|
1
|
148
|
(4)
|
1
|
Seroxat/Paxil
|
124
|
(9)
|
(6)
|
-
|
-
|
-
|
29
|
-
|
-
|
95
|
(12)
|
(7)
|
Valtrex
|
90
|
(7)
|
(3)
|
14
|
(12)
|
(6)
|
23
|
-
|
-
|
53
|
(9)
|
(3)
|
Other
|
1,800
|
(13)
|
(9)
|
272
|
(34)
|
(31)
|
333
|
(6)
|
(7)
|
1,195
|
(8)
|
(3)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
12,459
|
(2)
|
2
|
5,334
|
(4)
|
2
|
2,962
|
1
|
(1)
|
4,163
|
(2)
|
4
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 September
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
645
|
39
|
40
|
395
|
36
|
37
|
151
|
51
|
50
|
99
|
34
|
39
|
Ellipta products
|
500
|
34
|
35
|
308
|
34
|
36
|
110
|
37
|
36
|
82
|
28
|
33
|
Anoro Ellipta
|
115
|
34
|
34
|
77
|
33
|
34
|
24
|
33
|
33
|
14
|
40
|
30
|
Arnuity Ellipta
|
10
|
43
|
43
|
9
|
50
|
50
|
-
|
-
|
-
|
1
|
-
|
-
|
Incruse Ellipta
|
75
|
34
|
38
|
51
|
31
|
33
|
18
|
38
|
38
|
6
|
50
|
75
|
Relvar/Breo Ellipta
|
258
|
15
|
16
|
139
|
9
|
11
|
59
|
20
|
20
|
60
|
22
|
24
|
Trelegy Ellipta
|
42
|
-
|
-
|
32
|
-
|
-
|
9
|
-
|
-
|
1
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
145
|
59
|
62
|
87
|
43
|
44
|
41
|
>100
|
>100
|
17
|
70
|
80
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,209
|
11
|
12
|
754
|
11
|
12
|
290
|
2
|
1
|
165
|
27
|
34
|
Dolutegravir products
|
1,138
|
16
|
17
|
733
|
13
|
14
|
267
|
12
|
11
|
138
|
42
|
51
|
Tivicay
|
432
|
19
|
21
|
271
|
11
|
12
|
93
|
16
|
15
|
68
|
70
|
85
|
Triumeq
|
669
|
8
|
9
|
427
|
5
|
6
|
172
|
9
|
8
|
70
|
23
|
26
|
Juluca
|
37
|
-
|
-
|
35
|
-
|
-
|
2
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
24
|
(51)
|
(47)
|
1
|
(50)
|
-
|
9
|
(65)
|
(65)
|
14
|
(33)
|
(29)
|
Selzentry
|
26
|
(16)
|
(13)
|
14
|
(18)
|
(18)
|
8
|
(27)
|
(27)
|
4
|
33
|
67
|
Other
|
21
|
(30)
|
(37)
|
6
|
(54)
|
(54)
|
6
|
(25)
|
(37)
|
9
|
-
|
(11)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
122
|
28
|
29
|
108
|
27
|
28
|
9
|
29
|
29
|
5
|
67
|
67
|
Benlysta
|
121
|
29
|
31
|
108
|
27
|
29
|
10
|
43
|
29
|
3
|
50
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,245
|
(11)
|
(9)
|
636
|
(18)
|
(17)
|
501
|
(10)
|
(11)
|
1,108
|
(8)
|
(4)
|
Established
Respiratory
|
1,021
|
(11)
|
(9)
|
451
|
(14)
|
(13)
|
200
|
(15)
|
(15)
|
370
|
(5)
|
(1)
|
Seretide/Advair
|
619
|
(17)
|
(15)
|
309
|
(20)
|
(19)
|
132
|
(20)
|
(20)
|
178
|
(7)
|
(2)
|
Flixotide/Flovent
|
117
|
(6)
|
(6)
|
59
|
(9)
|
(11)
|
19
|
6
|
6
|
39
|
(7)
|
(2)
|
Ventolin
|
172
|
8
|
12
|
83
|
26
|
29
|
29
|
(6)
|
(3)
|
60
|
(3)
|
2
|
Avamys/Veramyst
|
60
|
-
|
2
|
-
|
-
|
-
|
15
|
-
|
(7)
|
45
|
5
|
9
|
Other Respiratory
|
53
|
(10)
|
(10)
|
-
|
-
|
-
|
5
|
(17)
|
(33)
|
48
|
(8)
|
(4)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
109
|
(5)
|
-
|
1
|
(50)
|
(50)
|
40
|
-
|
-
|
68
|
(7)
|
1
|
Augmentin
|
133
|
(10)
|
(5)
|
-
|
-
|
-
|
40
|
(2)
|
(2)
|
93
|
(13)
|
(7)
|
Avodart
|
144
|
-
|
1
|
3
|
-
|
33
|
59
|
(11)
|
(12)
|
82
|
9
|
12
|
Imigran/Imitrex
|
33
|
(13)
|
(13)
|
13
|
(19)
|
(19)
|
13
|
(19)
|
(19)
|
7
|
17
|
17
|
Lamictal
|
148
|
(11)
|
(10)
|
74
|
(14)
|
(13)
|
30
|
11
|
11
|
44
|
(19)
|
(17)
|
Seroxat/Paxil
|
42
|
(9)
|
(4)
|
-
|
-
|
-
|
9
|
(10)
|
-
|
33
|
(8)
|
(6)
|
Valtrex
|
32
|
(6)
|
(3)
|
6
|
(14)
|
(14)
|
8
|
-
|
-
|
18
|
(5)
|
-
|
Other
|
583
|
(16)
|
(14)
|
88
|
(36)
|
(37)
|
102
|
(11)
|
(12)
|
393
|
(12)
|
(8)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,221
|
1
|
3
|
1,893
|
3
|
4
|
951
|
1
|
-
|
1,377
|
(3)
|
2
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - six months ended 30 June
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
1,140
|
32
|
39
|
671
|
21
|
30
|
279
|
56
|
54
|
190
|
46
|
55
|
Ellipta products
|
895
|
22
|
29
|
524
|
13
|
22
|
212
|
39
|
37
|
159
|
37
|
47
|
Anoro Ellipta
|
217
|
48
|
56
|
143
|
44
|
56
|
48
|
55
|
52
|
26
|
53
|
71
|
Arnuity Ellipta
|
21
|
31
|
44
|
19
|
19
|
25
|
-
|
-
|
-
|
2
|
>100
|
>100
|
Incruse Ellipta
|
122
|
45
|
52
|
75
|
39
|
50
|
36
|
57
|
57
|
11
|
57
|
57
|
Relvar/Breo Ellipta
|
498
|
3
|
8
|
256
|
(13)
|
(6)
|
123
|
24
|
23
|
119
|
29
|
37
|
Trelegy Ellipta
|
37
|
-
|
-
|
31
|
-
|
-
|
5
|
-
|
-
|
1
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
245
|
86
|
95
|
147
|
60
|
73
|
67
|
>100
|
>100
|
31
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
2,237
|
7
|
12
|
1,373
|
5
|
14
|
587
|
9
|
8
|
277
|
7
|
14
|
Dolutegravir products
|
2,077
|
14
|
20
|
1,331
|
9
|
17
|
533
|
24
|
22
|
213
|
21
|
30
|
Tivicay
|
755
|
18
|
25
|
484
|
14
|
24
|
180
|
22
|
20
|
91
|
28
|
39
|
Triumeq
|
1,288
|
9
|
14
|
814
|
2
|
10
|
352
|
25
|
23
|
122
|
16
|
23
|
Juluca
|
34
|
-
|
-
|
33
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
63
|
(56)
|
(54)
|
2
|
(90)
|
(90)
|
24
|
(66)
|
(66)
|
37
|
(26)
|
(20)
|
Selzentry
|
58
|
(13)
|
(9)
|
28
|
(15)
|
(6)
|
18
|
(14)
|
(14)
|
12
|
(8)
|
(8)
|
Other
|
39
|
(37)
|
(37)
|
12
|
(52)
|
(56)
|
12
|
(29)
|
(29)
|
15
|
(25)
|
(20)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
214
|
16
|
24
|
191
|
14
|
23
|
17
|
31
|
31
|
6
|
20
|
40
|
Benlysta
|
214
|
16
|
25
|
191
|
15
|
23
|
17
|
31
|
31
|
6
|
20
|
60
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
4,647
|
(14)
|
(10)
|
1,206
|
(28)
|
(23)
|
1,128
|
(11)
|
(12)
|
2,313
|
(5)
|
1
|
Established
Respiratory
|
2,131
|
(19)
|
(14)
|
828
|
(30)
|
(24)
|
488
|
(13)
|
(14)
|
815
|
(7)
|
(1)
|
Seretide/Advair
|
1,156
|
(28)
|
(24)
|
489
|
(40)
|
(35)
|
317
|
(18)
|
(19)
|
350
|
(12)
|
(7)
|
Flixotide/Flovent
|
312
|
1
|
7
|
180
|
8
|
16
|
48
|
(6)
|
(6)
|
84
|
(8)
|
(1)
|
Ventolin
|
350
|
(11)
|
(5)
|
159
|
(22)
|
(16)
|
65
|
-
|
(2)
|
126
|
1
|
10
|
Avamys/Veramyst
|
167
|
7
|
12
|
-
|
-
|
-
|
42
|
(5)
|
(5)
|
125
|
11
|
18
|
Other Respiratory
|
146
|
(10)
|
(7)
|
-
|
-
|
-
|
16
|
7
|
-
|
130
|
(13)
|
(9)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
211
|
(6)
|
(1)
|
1
|
-
|
-
|
78
|
(5)
|
(6)
|
132
|
(7)
|
1
|
Augmentin
|
291
|
(2)
|
4
|
-
|
-
|
-
|
92
|
(3)
|
(5)
|
199
|
(1)
|
8
|
Avodart
|
279
|
(13)
|
(10)
|
6
|
(33)
|
(22)
|
121
|
(28)
|
(28)
|
152
|
6
|
12
|
Imigran/Imitrex
|
68
|
(28)
|
(27)
|
26
|
(43)
|
(41)
|
30
|
(12)
|
(12)
|
12
|
(14)
|
(14)
|
Lamictal
|
310
|
(2)
|
4
|
153
|
(5)
|
2
|
53
|
(2)
|
(4)
|
104
|
4
|
10
|
Seroxat/Paxil
|
82
|
(10)
|
(7)
|
-
|
-
|
-
|
20
|
5
|
-
|
62
|
(14)
|
(8)
|
Valtrex
|
58
|
(8)
|
(3)
|
8
|
(11)
|
-
|
15
|
-
|
-
|
35
|
(10)
|
(5)
|
Other
|
1,217
|
(11)
|
(7)
|
184
|
(33)
|
(28)
|
231
|
(4)
|
(5)
|
802
|
(7)
|
-
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
8,238
|
(4)
|
1
|
3,441
|
(7)
|
-
|
2,011
|
-
|
(1)
|
2,786
|
(2)
|
5
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 30 June
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
650
|
31
|
37
|
405
|
21
|
28
|
145
|
53
|
53
|
100
|
47
|
59
|
Ellipta products
|
509
|
20
|
26
|
317
|
12
|
18
|
109
|
36
|
36
|
83
|
38
|
50
|
Anoro Ellipta
|
120
|
41
|
48
|
83
|
41
|
47
|
24
|
41
|
35
|
13
|
44
|
78
|
Arnuity Ellipta
|
10
|
25
|
38
|
9
|
13
|
13
|
-
|
-
|
-
|
1
|
-
|
-
|
Incruse Ellipta
|
74
|
48
|
54
|
48
|
41
|
50
|
20
|
54
|
54
|
6
|
100
|
100
|
Relvar/Breo Ellipta
|
279
|
(1)
|
4
|
156
|
(15)
|
(10)
|
61
|
22
|
24
|
62
|
29
|
35
|
Trelegy Ellipta
|
26
|
-
|
-
|
21
|
-
|
-
|
4
|
-
|
-
|
1
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
141
|
93
|
>100
|
88
|
76
|
86
|
36
|
>100
|
>100
|
17
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,189
|
7
|
11
|
744
|
7
|
13
|
288
|
3
|
4
|
157
|
11
|
16
|
Dolutegravir products
|
1,113
|
13
|
18
|
727
|
10
|
16
|
263
|
16
|
17
|
123
|
24
|
31
|
Tivicay
|
407
|
20
|
25
|
256
|
15
|
21
|
92
|
18
|
19
|
59
|
51
|
62
|
Triumeq
|
682
|
5
|
9
|
448
|
2
|
7
|
170
|
15
|
16
|
64
|
7
|
12
|
Juluca
|
24
|
-
|
-
|
23
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
26
|
(59)
|
(56)
|
(1)
|
>(100)
|
>(100)
|
10
|
(69)
|
(69)
|
17
|
(29)
|
(21)
|
Selzentry
|
29
|
-
|
-
|
13
|
-
|
8
|
9
|
(18)
|
(18)
|
7
|
40
|
20
|
Other
|
21
|
(43)
|
(46)
|
5
|
(55)
|
(73)
|
6
|
(45)
|
(45)
|
10
|
(31)
|
(23)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
114
|
23
|
29
|
102
|
23
|
30
|
9
|
29
|
29
|
3
|
-
|
-
|
Benlysta
|
114
|
23
|
29
|
102
|
23
|
29
|
8
|
14
|
29
|
4
|
33
|
33
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,276
|
(14)
|
(11)
|
620
|
(28)
|
(25)
|
542
|
(11)
|
(11)
|
1,114
|
(5)
|
-
|
Established
Respiratory
|
1,046
|
(20)
|
(17)
|
432
|
(32)
|
(29)
|
234
|
(12)
|
(12)
|
380
|
(6)
|
(2)
|
Seretide/Advair
|
590
|
(30)
|
(28)
|
260
|
(45)
|
(43)
|
151
|
(17)
|
(17)
|
179
|
(6)
|
(2)
|
Flixotide/Flovent
|
154
|
6
|
12
|
94
|
21
|
27
|
21
|
(9)
|
(4)
|
39
|
(11)
|
(7)
|
Ventolin
|
170
|
(5)
|
-
|
78
|
(9)
|
(6)
|
31
|
3
|
3
|
61
|
(3)
|
6
|
Avamys/Veramyst
|
69
|
6
|
11
|
-
|
-
|
-
|
22
|
(4)
|
-
|
47
|
9
|
14
|
Other Respiratory
|
63
|
(6)
|
(10)
|
-
|
-
|
-
|
9
|
29
|
-
|
54
|
(14)
|
(17)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
104
|
(6)
|
(2)
|
-
|
-
|
-
|
39
|
(5)
|
(5)
|
65
|
(7)
|
-
|
Augmentin
|
127
|
(10)
|
(5)
|
-
|
-
|
-
|
37
|
(12)
|
(12)
|
90
|
(9)
|
(2)
|
Avodart
|
138
|
(14)
|
(11)
|
3
|
(25)
|
(25)
|
57
|
(32)
|
(32)
|
78
|
8
|
14
|
Imigran/Imitrex
|
36
|
(12)
|
(12)
|
14
|
(13)
|
(12)
|
15
|
(17)
|
(17)
|
7
|
-
|
-
|
Lamictal
|
164
|
10
|
13
|
82
|
14
|
19
|
27
|
(4)
|
(7)
|
55
|
12
|
16
|
Seroxat/Paxil
|
42
|
(9)
|
(9)
|
-
|
-
|
-
|
10
|
-
|
(10)
|
32
|
(11)
|
(8)
|
Valtrex
|
30
|
(6)
|
(3)
|
5
|
-
|
-
|
8
|
-
|
-
|
17
|
(11)
|
(5)
|
Other
|
589
|
(12)
|
(7)
|
84
|
(35)
|
(34)
|
115
|
-
|
3
|
390
|
(8)
|
(2)
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,229
|
(3)
|
1
|
1,871
|
(5)
|
-
|
984
|
(1)
|
(1)
|
1,374
|
(1)
|
4
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Pharmaceuticals turnover - three months ended 31 March
2018
|
|
Total
|
US
|
Europe
|
International
|
||||||||
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
-------------------------------------
|
||||||||
|
|
Growth
|
|
Growth
|
|
Growth
|
|
Growth
|
||||
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
|
-----------------------
|
||||
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
£m
|
£%
|
CER%
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Respiratory
|
490
|
34
|
42
|
266
|
20
|
34
|
134
|
60
|
56
|
90
|
45
|
52
|
Ellipta products
|
386
|
25
|
34
|
207
|
16
|
29
|
103
|
41
|
38
|
76
|
36
|
43
|
Anoro Ellipta
|
97
|
56
|
68
|
60
|
50
|
67
|
24
|
71
|
71
|
13
|
62
|
62
|
Arnuity Ellipta
|
11
|
37
|
50
|
10
|
25
|
37
|
-
|
-
|
-
|
1
|
>100
|
>100
|
Incruse Ellipta
|
48
|
41
|
50
|
27
|
35
|
50
|
16
|
60
|
60
|
5
|
25
|
25
|
Relvar/Breo Ellipta
|
219
|
7
|
14
|
100
|
(10)
|
1
|
62
|
27
|
22
|
57
|
30
|
39
|
Trelegy Ellipta
|
11
|
-
|
-
|
10
|
-
|
-
|
1
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Nucala/Mepolizumab
|
104
|
76
|
86
|
59
|
40
|
57
|
31
|
>100
|
>100
|
14
|
>100
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
HIV
|
1,048
|
6
|
14
|
629
|
3
|
15
|
299
|
15
|
12
|
120
|
3
|
11
|
Dolutegravir products
|
964
|
15
|
23
|
604
|
8
|
20
|
270
|
32
|
28
|
90
|
17
|
27
|
Tivicay
|
348
|
15
|
24
|
228
|
14
|
27
|
88
|
26
|
21
|
32
|
-
|
13
|
Triumeq
|
606
|
12
|
20
|
366
|
2
|
13
|
182
|
36
|
32
|
58
|
29
|
38
|
Juluca
|
10
|
-
|
-
|
10
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Epzicom/Kivexa
|
37
|
(53)
|
(52)
|
3
|
(79)
|
(79)
|
14
|
(64)
|
(64)
|
20
|
(23)
|
(19)
|
Selzentry
|
29
|
(24)
|
(16)
|
15
|
(25)
|
(15)
|
9
|
(10)
|
(10)
|
5
|
(37)
|
(25)
|
Other
|
18
|
(30)
|
(26)
|
7
|
(50)
|
(43)
|
6
|
-
|
-
|
5
|
(14)
|
(14)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Immuno-inflammation
|
100
|
9
|
20
|
89
|
6
|
17
|
8
|
33
|
33
|
3
|
50
|
100
|
Benlysta
|
100
|
10
|
21
|
89
|
7
|
18
|
9
|
50
|
33
|
2
|
-
|
>100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Oncology
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Established
Pharmaceuticals
|
2,371
|
(14)
|
(8)
|
586
|
(28)
|
(21)
|
586
|
(11)
|
(13)
|
1,199
|
(5)
|
2
|
Established
Respiratory
|
1,085
|
(18)
|
(12)
|
396
|
(27)
|
(20)
|
254
|
(15)
|
(17)
|
435
|
(8)
|
-
|
Seretide/Advair
|
566
|
(25)
|
(20)
|
229
|
(32)
|
(25)
|
166
|
(19)
|
(21)
|
171
|
(17)
|
(12)
|
Flixotide/Flovent
|
158
|
(4)
|
4
|
86
|
(3)
|
7
|
27
|
(4)
|
(7)
|
45
|
(4)
|
4
|
Ventolin
|
180
|
(16)
|
(9)
|
81
|
(31)
|
(23)
|
34
|
(3)
|
(6)
|
65
|
5
|
15
|
Avamys/Veramyst
|
98
|
8
|
13
|
-
|
-
|
-
|
20
|
(5)
|
(10)
|
78
|
11
|
20
|
Other Respiratory
|
83
|
(13)
|
(4)
|
-
|
-
|
-
|
7
|
(12)
|
-
|
76
|
(12)
|
(2)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Dermatology
|
107
|
(5)
|
-
|
1
|
>100
|
>100
|
39
|
(5)
|
(7)
|
67
|
(7)
|
3
|
Augmentin
|
164
|
6
|
12
|
-
|
-
|
-
|
55
|
4
|
-
|
109
|
7
|
19
|
Avodart
|
141
|
(12)
|
(9)
|
3
|
(40)
|
(20)
|
64
|
(23)
|
(24)
|
74
|
3
|
10
|
Imigran/Imitrex
|
32
|
(40)
|
(38)
|
12
|
(60)
|
(57)
|
15
|
(6)
|
(6)
|
5
|
(29)
|
(29)
|
Lamictal
|
146
|
(12)
|
(5)
|
71
|
(20)
|
(11)
|
26
|
-
|
-
|
49
|
(4)
|
4
|
Seroxat/Paxil
|
40
|
(11)
|
(4)
|
-
|
-
|
-
|
10
|
11
|
11
|
30
|
(17)
|
(8)
|
Valtrex
|
28
|
(10)
|
(3)
|
3
|
(25)
|
-
|
7
|
-
|
-
|
18
|
(10)
|
(5)
|
Other
|
628
|
(11)
|
(6)
|
100
|
(31)
|
(24)
|
116
|
(8)
|
(12)
|
412
|
(6)
|
1
|
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
--------
|
Pharmaceuticals
|
4,009
|
(4)
|
2
|
1,570
|
(9)
|
1
|
1,027
|
2
|
(1)
|
1,412
|
(3)
|
5
|
|
--------
|
--------
|
--------
|
--------
|
----------
|
--------
|
--------
|
---------
|
--------
|
--------
|
---------
|
--------
|
Total income statement
|
|
2018
|
||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Quarter 1
|
|
Quarter 2
|
|
6 months
|
|
Quarter 3
|
|
9 months
|
|
Quarter 4
|
|
Full Year
|
|
£m
|
|
£m
|
|
£m
|
|
£m
|
|
£m
|
|
£m
|
|
£m
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Turnover
|
7,222
|
|
7,310
|
|
14,532
|
|
8,092
|
|
22,624
|
|
8,197
|
|
30,821
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cost of sales
|
(2,390)
|
|
(2,311)
|
|
(4,701)
|
|
(2,637)
|
|
(7,338)
|
|
(2,906)
|
|
(10,244)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross profit
|
4,832
|
|
4,999
|
|
9,831
|
|
5,455
|
|
15,286
|
|
5,291
|
|
20,577
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling, general and administration
|
(2,304)
|
|
(2,452)
|
|
(4,756)
|
|
(2,524)
|
|
(7,280)
|
|
(2,617)
|
|
(9,897)
|
Research and development
|
(903)
|
|
(924)
|
|
(1,827)
|
|
(988)
|
|
(2,815)
|
|
(1,075)
|
|
(3,890)
|
Royalty income
|
53
|
|
73
|
|
126
|
|
94
|
|
220
|
|
79
|
|
299
|
Other operating income/(expense)
|
(429)
|
|
(912)
|
|
(1,341)
|
|
(125)
|
|
(1,466)
|
|
(122)
|
|